Experimental cancer drug combo tested in early trial
NCT ID NCT04157517
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested the safety and dosing of a new drug called modakafusp alfa, given alone or with pembrolizumab, in adults with advanced solid tumors or melanoma. The study aimed to find the highest safe dose and check for side effects. It was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
modakafusp alfa (TAK-573) and pembrolizumab
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors, including melanoma.
What could go wrong
The trial was terminated early, so results are limited. It was a small, early-phase study focused on safety, not proof of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Avera Cancer Institute
Sioux Falls, South Dakota, 57105, United States
-
Ballarat Regional Integrated Cancer Center
Ballarat, Victoria, 3350, Australia
-
City of Hope Comprehensive Cancer Center - Duarte
Duarte, California, 91010, United States
-
Cleveland Clinic Main Campus
Cleveland, Ohio, 44195, United States
-
Intermountain Medical Center
Murray, Utah, 84107, United States
-
Morristown Medical Center
Morristown, New Jersey, 07960, United States
-
Norris Cotton Cancer Center Lebanon
Lebanon, New Hampshire, 03756, United States
-
Orlando Health Cancer Institute
Orlando, Florida, 32806, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246, United States
-
The Angeles Clinic and Research Institute - West Los Angeles Office
Los Angeles, California, 90025, United States
-
The Queen Elizabeth Hospital
Woodville South, South Australia, 5011, Australia
-
University of California San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
University of Colorado Health Memorial Hospital Central
Colorado Springs, Colorado, 80909, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
-
West Virginia University Health Sciences Campus
Morgantown, West Virginia, 26506, United States